Stryker to Acquire Artelon, Expanding Soft Tissue Fixation Solutions

June 5, 2024

Strengthening Innovation in Soft Tissue Reconstruction

Stryker (NYSE: SYK), a global medical technology leader, has signed an agreement to acquire Artelon, a company specializing in soft tissue fixation products for foot and ankle and sports medicine procedures. This acquisition aims to bolster Stryker’s capabilities in ligament and tendon reconstruction.


Artelon’s synthetic technology enhances biological and mechanical reconstruction, with over 60,000 implantations globally. The purchase will help Stryker offer more innovative biomaterial solutions, enhancing its competitiveness in the market.


Tim Lanier, president of Stryker’s Trauma & Extremities division, emphasized that Artelon’s product portfolio will strengthen Stryker’s offerings and support their mission to provide high-quality healthcare solutions.


The transaction is subject to customary closing conditions, with both companies operating independently until then.


Read the full release here.

RECENT ARTICLES

New Savings Program: MichBio & SU Group

May 5, 2025
MichBio is eager to launch a new cost savings program with SU Group, designed to help life science companies cut lab equipment service costs and streamline contract management. SU Group consolidates multiple service agreements into one flexible, cost-effective solution, covering parts, labor, and travel for emergency and preventive maintenance. Plus, MichBio members benefit from dedicated support, reduction of purchase orders, and comprehensive coverage. Take the hassle out of equipment maintenance and keep your lab running smoothly. >> Learn more

Upcoming Webinar - Prenuptial Patenting

April 24, 2025
Prenuptial Patenting: Responsible Engagement with Engineering Firms

Member Feature: PharmOptima

April 24, 2025
PharmOptima, a Poratge, Michigan-based preclinical contract research organization (CRO) is advancing drug discovery through its comprehensive suite of services. Specializing in in-vivo ADME/PK, ocular research, as well as regulated large and small molecule bioanalytical and ligand binding services, PharmOptima supports clients in optimizing drug development programs efficiently and effectively. With a staff averaging 11 years of industry experience and multiple individuals with advanced degrees, PharmOptima also boasts one of the most capable and engaging teams in the industry. The company collaborates with board-certified veterinary ophthalmologist Dr. Ryan Boyd, further enhancing its ocular research capabilities. PharmOptima's team of experts is dedicated to providing high-quality services to the pharmaceutical biotechnology industries. Looking ahead, PharmOptima scientists will be presenting posters at the 2025 The Association for Research in Vision and Ophthalmology (ARVO) conference, showcasing their latest research and innovations in ocular drug development. For more information visit www.pharmoptima.com .